Response to therapy with direct antiviral drugs in HCV-infected patients with diabetes
Abstract The clinical and metabolic interactions between hepatitis C virus (HCV) infection and diabetes mellitus (DM) are well documented. The study aimed to compare HCV-infected patients with and without DM. The analysis included 18,968 patients treated with direct-acting antivirals (DAAs) between...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-025-06290-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849238268703408128 |
|---|---|
| author | Michał Brzdęk Dorota Zarębska-Michaluk Piotr Rzymski Beata Lorenc Justyna Janocha-Litwin Hanna Berak Krzysztof Tomasiewicz Marek Sitko Włodzimierz Mazur Ewa Janczewska Dorota Dybowska Jakub Klapaczyński Anna Parfieniuk-Kowerda Jerzy Jaroszewicz Anna Piekarska Robert Flisiak |
| author_facet | Michał Brzdęk Dorota Zarębska-Michaluk Piotr Rzymski Beata Lorenc Justyna Janocha-Litwin Hanna Berak Krzysztof Tomasiewicz Marek Sitko Włodzimierz Mazur Ewa Janczewska Dorota Dybowska Jakub Klapaczyński Anna Parfieniuk-Kowerda Jerzy Jaroszewicz Anna Piekarska Robert Flisiak |
| author_sort | Michał Brzdęk |
| collection | DOAJ |
| description | Abstract The clinical and metabolic interactions between hepatitis C virus (HCV) infection and diabetes mellitus (DM) are well documented. The study aimed to compare HCV-infected patients with and without DM. The analysis included 18,968 patients treated with direct-acting antivirals (DAAs) between 2015 and 2023, whose data were collected retrospectively. In the study population, 2179 patients (11.5%) were diagnosed with DM. Compared to the non-diabetic population, they were male-dominated (p = 0.003), had a significantly higher proportion of patients aged ≥ 50 years (p < 0.001), and were more burdened with comorbidities (p < 0.001). The most common HCV genotype was 1b with a significantly higher prevalence in the diabetic group (p < 0.001). Liver disease advancement was higher in diabetic patients, with 17.9% advanced fibrosis and 48% cirrhosis compared to 13.2% (p < 0.001) and 21.8% (p < 0.001) in the non-diabetic population. The effectiveness of DAA therapy in patients with DM was significantly lower compared to the population without diabetes, both in intent-to-treat analysis 93.1% vs. 94.6%, p = 0.015, and per-protocol analysis 96.8% vs. 97.7%, p = 0.0128, however, logistic regression analysis did not confirm the role of diabetes as an independent predictor of treatment failure, suggesting that in the absence of other negative prognostic factors, DM alone does not reduce the chances of cure. |
| format | Article |
| id | doaj-art-faadca81eb8240e6847ae2a1a7a11af8 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-faadca81eb8240e6847ae2a1a7a11af82025-08-20T04:01:41ZengNature PortfolioScientific Reports2045-23222025-07-0115111210.1038/s41598-025-06290-5Response to therapy with direct antiviral drugs in HCV-infected patients with diabetesMichał Brzdęk0Dorota Zarębska-Michaluk1Piotr Rzymski2Beata Lorenc3Justyna Janocha-Litwin4Hanna Berak5Krzysztof Tomasiewicz6Marek Sitko7Włodzimierz Mazur8Ewa Janczewska9Dorota Dybowska10Jakub Klapaczyński11Anna Parfieniuk-Kowerda12Jerzy Jaroszewicz13Anna Piekarska14Robert Flisiak15Collegium Medicum, Jan Kochanowski UniversityDepartment of Infectious Diseases and Allergology, Jan Kochanowski UniversityDepartment of Environmental Medicine, Poznan University of Medical SciencesPomeranian Center of Infectious Diseases, Medical UniversityDepartment of Infectious Diseases and Hepatology, Wrocław Medical UniversityOutpatient Clinic, Hospital for Infectious Diseases in WarsawDepartment of Infectious Diseases, Medical University of LublinDepartment of Infectious and Tropical Diseases, Jagiellonian UniversityClinical Department of Infectious Diseases in Chorzów, Medical University of SilesiaDepartment of Basic Medical Sciences, School of Public Health in Bytom, Medical University of SilesiaDepartment of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum Bydgoszcz, Nicolaus Copernicus UniversityDepartment of Internal Medicine and Hepatology, The National Institute of Medicine of the Ministry of Interior and AdministrationDepartment of Infectious Diseases and Hepatology, Medical University of BiałystokDepartment of Infectious Diseases and Hepatology, Medical University of SilesiaDepartment of Infectious Diseases and Hepatology, Medical University of ŁódźDepartment of Infectious Diseases and Hepatology, Medical University of BiałystokAbstract The clinical and metabolic interactions between hepatitis C virus (HCV) infection and diabetes mellitus (DM) are well documented. The study aimed to compare HCV-infected patients with and without DM. The analysis included 18,968 patients treated with direct-acting antivirals (DAAs) between 2015 and 2023, whose data were collected retrospectively. In the study population, 2179 patients (11.5%) were diagnosed with DM. Compared to the non-diabetic population, they were male-dominated (p = 0.003), had a significantly higher proportion of patients aged ≥ 50 years (p < 0.001), and were more burdened with comorbidities (p < 0.001). The most common HCV genotype was 1b with a significantly higher prevalence in the diabetic group (p < 0.001). Liver disease advancement was higher in diabetic patients, with 17.9% advanced fibrosis and 48% cirrhosis compared to 13.2% (p < 0.001) and 21.8% (p < 0.001) in the non-diabetic population. The effectiveness of DAA therapy in patients with DM was significantly lower compared to the population without diabetes, both in intent-to-treat analysis 93.1% vs. 94.6%, p = 0.015, and per-protocol analysis 96.8% vs. 97.7%, p = 0.0128, however, logistic regression analysis did not confirm the role of diabetes as an independent predictor of treatment failure, suggesting that in the absence of other negative prognostic factors, DM alone does not reduce the chances of cure.https://doi.org/10.1038/s41598-025-06290-5 |
| spellingShingle | Michał Brzdęk Dorota Zarębska-Michaluk Piotr Rzymski Beata Lorenc Justyna Janocha-Litwin Hanna Berak Krzysztof Tomasiewicz Marek Sitko Włodzimierz Mazur Ewa Janczewska Dorota Dybowska Jakub Klapaczyński Anna Parfieniuk-Kowerda Jerzy Jaroszewicz Anna Piekarska Robert Flisiak Response to therapy with direct antiviral drugs in HCV-infected patients with diabetes Scientific Reports |
| title | Response to therapy with direct antiviral drugs in HCV-infected patients with diabetes |
| title_full | Response to therapy with direct antiviral drugs in HCV-infected patients with diabetes |
| title_fullStr | Response to therapy with direct antiviral drugs in HCV-infected patients with diabetes |
| title_full_unstemmed | Response to therapy with direct antiviral drugs in HCV-infected patients with diabetes |
| title_short | Response to therapy with direct antiviral drugs in HCV-infected patients with diabetes |
| title_sort | response to therapy with direct antiviral drugs in hcv infected patients with diabetes |
| url | https://doi.org/10.1038/s41598-025-06290-5 |
| work_keys_str_mv | AT michałbrzdek responsetotherapywithdirectantiviraldrugsinhcvinfectedpatientswithdiabetes AT dorotazarebskamichaluk responsetotherapywithdirectantiviraldrugsinhcvinfectedpatientswithdiabetes AT piotrrzymski responsetotherapywithdirectantiviraldrugsinhcvinfectedpatientswithdiabetes AT beatalorenc responsetotherapywithdirectantiviraldrugsinhcvinfectedpatientswithdiabetes AT justynajanochalitwin responsetotherapywithdirectantiviraldrugsinhcvinfectedpatientswithdiabetes AT hannaberak responsetotherapywithdirectantiviraldrugsinhcvinfectedpatientswithdiabetes AT krzysztoftomasiewicz responsetotherapywithdirectantiviraldrugsinhcvinfectedpatientswithdiabetes AT mareksitko responsetotherapywithdirectantiviraldrugsinhcvinfectedpatientswithdiabetes AT włodzimierzmazur responsetotherapywithdirectantiviraldrugsinhcvinfectedpatientswithdiabetes AT ewajanczewska responsetotherapywithdirectantiviraldrugsinhcvinfectedpatientswithdiabetes AT dorotadybowska responsetotherapywithdirectantiviraldrugsinhcvinfectedpatientswithdiabetes AT jakubklapaczynski responsetotherapywithdirectantiviraldrugsinhcvinfectedpatientswithdiabetes AT annaparfieniukkowerda responsetotherapywithdirectantiviraldrugsinhcvinfectedpatientswithdiabetes AT jerzyjaroszewicz responsetotherapywithdirectantiviraldrugsinhcvinfectedpatientswithdiabetes AT annapiekarska responsetotherapywithdirectantiviraldrugsinhcvinfectedpatientswithdiabetes AT robertflisiak responsetotherapywithdirectantiviraldrugsinhcvinfectedpatientswithdiabetes |